<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296335</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-ONCGI-0204</org_study_id>
    <nct_id>NCT00296335</nct_id>
  </id_info>
  <brief_title>Trial of Adjuvant Chemotherapy for Gastric Cancer</brief_title>
  <official_title>A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Advanced Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III randomized study designed to evaluate the efficacy of mitomycin,
      doxifluridine, and cisplatin compared to mitomycin and doxifluridine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stomach cancer is the most common cancer in Korea and one of the major health problems
      worldwide. The most effective treatment for gastric cancer is curative surgical resection of
      primary tumor. However, a substantial number of patients eventually die of recurrences after
      curative resection. A number of randomized trials investigating the role of adjuvant
      chemotherapy have been conducted. However, the efficacy of adjuvant chemotherapy is still
      controversial and varied between Western and Asian trials. Meta-analysis of Western trials
      didn't demonstrate the benefit of adjuvant chemotherapy after curative resection. Conversely,
      some Asian studies have demonstrated the efficacy of adjuvant chemotherapy after curative
      resection. In a previous study, mitomycin plus tegafur prolonged the survival in resected
      gastric cancer compared to no treatment.

      This study is designed to evaluate the efficacy of mitomycin, cisplatin and prolonged
      treatment with doxifluridine compared to mitomycin plus doxifluridine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free Survival Rate</measure>
    <time_frame>3 years</time_frame>
    <description>Relapse-free survival at 3 years was defined as the proportion of patients who did not show an evidence of disease recurrence after 3 years of surgery.
Relapse was defined as any new tumor lesion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival rate at 3 years was defined as the proportion of patients who were alive at 3 years after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Per National Cancer Institute Common Toxicity Criteria version 2.0, up to 3 years</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">855</enrollment>
  <condition>Stomach Cancer</condition>
  <arm_group>
    <arm_group_label>Mitomycin and doxifluridine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitomycin, doxifluridine and cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin, doxifluridine and cisplatin</intervention_name>
    <description>Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)</description>
    <arm_group_label>Mitomycin, doxifluridine and cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin and doxifluridine</intervention_name>
    <description>Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)</description>
    <arm_group_label>Mitomycin and doxifluridine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically proven gastric adenocarcinoma

          -  Curative resection was done

          -  stage II, IIIA, IIIB, IV (including T4, lesions or N3, but excluding M1 lymph node
             metastasis)

          -  age: 18-69 years old

          -  Performance status: ECOG 0-2

          -  Adequate bone marrow function (WBC ≥ 4,000/ul, platelet count ≥ 100,000/ul, hemoglobin
             ≥ 10 g/dl)

          -  Adequate renal function (serum creatinine≤ 1.5)

          -  Adequate liver function (serum bilirubin ≤1.5 mg/dl, AST/ALT ≤ 3 x normal upper limit)

          -  Written informed consent was signed by the patient

        Exclusion Criteria:

          -  Previous chemotherapy or radiotherapy

          -  Active ongoing infection which antibiotic treatment is needed

          -  Pregnant or lactating women

          -  Psychosis or convulsion disorder

          -  Ascites in preoperative abdomen CT

          -  Systemic disease which interfere the administration of chemotherapy

          -  Previous history of other malignancy except cured non-malignant skin cancer and
             uterine cervical cancer in situ
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Koo Kang, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2006</study_first_submitted>
  <study_first_submitted_qc>February 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2006</study_first_posted>
  <results_first_submitted>November 12, 2013</results_first_submitted>
  <results_first_submitted_qc>January 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2014</results_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stomach cancer</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>Mitomycin</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Doxifluridine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxifluridine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>AMC0201 was an open-label, prospective randomised phase 3 clinical trial conducted at three centres (Asan medical center, Hallym University medical center, and Ulsan university hospital) in Korea. Patients were enrolled between February 2002 and August 2006</recruitment_details>
      <pre_assignment_details>All enrolled patients received study treatments</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mitomycin and Doxifluridine</title>
          <description>Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)</description>
        </group>
        <group group_id="P2">
          <title>Mitomycin, Doxifluridine and Cisplatin</title>
          <description>Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="424"/>
                <participants group_id="P2" count="431"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="394"/>
                <participants group_id="P2" count="309"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Recurrence</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled patients were included in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Mitomycin and Doxifluridine</title>
          <description>Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)</description>
        </group>
        <group group_id="B2">
          <title>Mitomycin, Doxifluridine and Cisplatin</title>
          <description>Experimental armMitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="424"/>
            <count group_id="B2" value="431"/>
            <count group_id="B3" value="855"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="361"/>
                    <measurement group_id="B2" value="380"/>
                    <measurement group_id="B3" value="741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="10.6"/>
                    <measurement group_id="B2" value="53.3" spread="10.1"/>
                    <measurement group_id="B3" value="53.3" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="294"/>
                    <measurement group_id="B2" value="294"/>
                    <measurement group_id="B3" value="588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="424"/>
                    <measurement group_id="B2" value="431"/>
                    <measurement group_id="B3" value="855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relapse-free Survival Rate</title>
        <description>Relapse-free survival at 3 years was defined as the proportion of patients who did not show an evidence of disease recurrence after 3 years of surgery.
Relapse was defined as any new tumor lesion.</description>
        <time_frame>3 years</time_frame>
        <population>Intention-to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Mitomycin Plus Short-term Fluoropyrimidine</title>
            <description>Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)</description>
          </group>
          <group group_id="O2">
            <title>Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati</title>
            <description>Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse-free Survival Rate</title>
          <description>Relapse-free survival at 3 years was defined as the proportion of patients who did not show an evidence of disease recurrence after 3 years of surgery.
Relapse was defined as any new tumor lesion.</description>
          <population>Intention-to treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" lower_limit="62.5" upper_limit="71.5"/>
                    <measurement group_id="O2" value="64.9" lower_limit="60.4" upper_limit="69.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Rate</title>
        <description>Overall survival rate at 3 years was defined as the proportion of patients who were alive at 3 years after surgery.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mitomycin Plus Short-term Fluoropyrimidine</title>
            <description>Control arm</description>
          </group>
          <group group_id="O2">
            <title>Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati</title>
            <description>Experimental arm</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Rate</title>
          <description>Overall survival rate at 3 years was defined as the proportion of patients who were alive at 3 years after surgery.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" lower_limit="72.9" upper_limit="80.9"/>
                    <measurement group_id="O2" value="73.1" lower_limit="68.9" upper_limit="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events</title>
        <description>Per National Cancer Institute Common Toxicity Criteria version 2.0, up to 3 years</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mitomycin Plus Short-term Fluoropyrimidine</title>
            <description>Control arm</description>
          </group>
          <group group_id="O2">
            <title>Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati</title>
            <description>Experimental arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events</title>
          <description>Per National Cancer Institute Common Toxicity Criteria version 2.0, up to 3 years</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
                <count group_id="O2" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                    <measurement group_id="O2" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393"/>
                    <measurement group_id="O2" value="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343"/>
                    <measurement group_id="O2" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293"/>
                    <measurement group_id="O2" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mitomycin Plus Short-term Fluoropyrimidine</title>
          <description>Control arm</description>
        </group>
        <group group_id="E2">
          <title>Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati</title>
          <description>Experimental arm</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI_CTC version 2.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI_CTC version 2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="393" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="413" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="262" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="387" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="393" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="413" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="293" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="371" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="288" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="343" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="391" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="326" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="389" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="301" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="261" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="334" subjects_at_risk="425"/>
              </event>
              <event>
                <sub_title>Hand-foot syndrome</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yoon-Koo Kang</name_or_title>
      <organization>Asan Medical Center</organization>
      <phone>+82-2-3010-3210</phone>
      <email>ykkang@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

